Bone Biologics Co. (NASDAQ:BBLG) Short Interest Down 13.9% in April

Bone Biologics Co. (NASDAQ:BBLG) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 13,000 shares, a decline of 13.9% from the March 31st total of 15,100 shares. Approximately 2.6% of the shares of the company are sold short. Based on an average daily volume of 80,600 shares, the short-interest ratio is presently 0.2 days.

Bone Biologics Stock Up 0.7 %

Shares of BBLG traded up $0.01 during midday trading on Friday, reaching $1.53. 28,507 shares of the stock were exchanged, compared to its average volume of 38,713. The business’s 50-day moving average price is $2.22 and its 200 day moving average price is $3.38. Bone Biologics has a twelve month low of $1.46 and a twelve month high of $72.00.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.